Solensia

RSS

frunevetmab

Authorised
This medicine is authorised for use in the European Union.

Overview

Solensia is a veterinary medicinal product, which contains the active substance frunevetmab. It is used in cats to relieve pain associated with osteoarthritis.
For more information, see the package leaflet.

This EPAR was last updated on 25/06/2020

Authorisation details

Product details
Name
Solensia
Agency product number
EMEA/V/C/005179
Active substance
frunevetmab
International non-proprietary name (INN) or common name
frunevetmab
Species
Cats
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Date of issue of marketing authorisation valid throughout the European Union
17/02/2021
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

17/02/2021 Solensia - EMEA/V/C/005179 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Analgesics

Therapeutic indication

For the alleviation of pain associated with osteoarthritis in cats.

Assessment history

How useful was this page?

Add your rating
Average
8 ratings
4 ratings
1 rating
1 rating